SCHEMBL893576

SCHEMBL893576

CCCCCCCCCCCCCC(=S)Nc1cc(C)c(O)c(C)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 2/20 0.47
SOAT2 O75908 1/20 0.47
ACAT1 P24752 1/20 0.47
NPY1R P25929 1/20 0.37
NPY2R P49146 1/20 0.37
PLA2G2A P14555 2/20 0.36
PLA2G5 P39877 2/20 0.36
FFAR1 O14842 1/20 0.36
ESR1 P03372 1/20 0.35
P2RX7 Q99572 1/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EP300 Q09472 1/20 0.33
HPGD P15428 1/20 0.33
TYR P14679 1/20 0.33
FNTA P49354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9446324 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446337 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446291 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446297 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446388 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446351 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446353 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL9446369 0.82 SOAT1 (0.53) SOAT1SOAT2ACAT1P2RX7GAA
SCHEMBL8049340 0.79 SOAT1 (0.45) SOAT1SOAT2ACAT1ESR1ALDH1A1
SCHEMBL8043457 0.78 SOAT1 (0.47) SOAT1SOAT2ACAT1NPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2453926-A2 PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE The Regents of the University of California (US) 2012-05-23 EP claimed
WO-2011008996-A2 PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-01-20 WO claimed
US-20100183598-A1 METHODS OF TREATING CARDIOVASCULAR DISORDERS CAROLUS THERAPEUTICS, INC. (US) 2010-07-22 US claimed
WO-2010056910-A2 METHODS OF TREATING CARDIOVASCULAR DISORDERS CAROLUS THERAPEUTICS, INC. (US) 2010-05-20 WO claimed
US-20230279048-A1 COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION 2023-09-07 US disclosed
US-11518782-B2 Compositions containing HC-HA/PTX3 complexes and methods of use thereof TISSUETECH, INC. (US) 2022-12-06 US disclosed
EP-3838293-A1 COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF Tissuetech, Inc. (US) 2021-06-23 EP disclosed
EP-2872181-B1 COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF TISSUETECH INC (US) 2020-11-18 EP disclosed
US-20200308219-A1 COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION 2020-10-01 US disclosed
US-10717763-B2 Compositions containing HC-HA/PTX3 complexes and methods of use thereof TISSUETECH, INC. (US) 2020-07-21 US disclosed
US-10597722-B2 Predictive analysis for myocardial infarction SCRIPPS HEALTH (US) 2020-03-24 US disclosed
US-20190169231-A1 COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION 2019-06-06 US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 US disclosed
US-20100183598-A1 METHODS OF TREATING CARDIOVASCULAR DISORDERS CAROLUS THERAPEUTICS, INC. (US) 2010-07-22 US disclosed
WO-2010065491-A2 METHODS OF TREATING INFLAMMATORY DISORDERS CAROLUS THERAPEUTICS, INC. (US) 2010-06-10 WO disclosed
WO-2010056910-A2 METHODS OF TREATING CARDIOVASCULAR DISORDERS CAROLUS THERAPEUTICS, INC. (US) 2010-05-20 WO disclosed
US-20100093636-A1 METHODS OF TREATING INFLAMMATION CAROLUS THERAPEUTICS, INC. (US) 2010-04-15 US disclosed
WO-2010042548-A2 METHODS OF TREATING INFLAMMATION CAROLUS THERAPEUTICS, INC. (US) 2010-04-15 WO disclosed
US-20090192220-A1 TREATMENT FOR SOLID TUMORS ORE PHARMACEUTICALS INC. (US) 2009-07-30 US disclosed
EP-0874812-B1 NOVEL 2,3,5-TRIMETHYL-4-HYDROXY ANILIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF PF MEDICAMENT (FR) 2000-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192220-A1 TREATMENT FOR SOLID TUMORS ACAT2, ACAT1, APRT SOAT1 65/4885SOAT2 125/4885ACAT1 2/4885
US-20100183598-A1 METHODS OF TREATING CARDIOVASCULAR DISORDERS TNNI3, TNNT2, FABP3 SOAT1 1163/4885SOAT2 1008/4885ACAT1 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.